^
Association details:
Biomarker:No biomarker
Cancer:Breast Cancer
Drug:Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Published date:
04/19/2022
Excerpt:
Recommendation...a patient with node-positive breast cancer with a high risk of recurrence and a Ki67 score of ≥ 20% as determined by an FDA-approved test may be offered two years of abemaciclib plus endocrine therapy...
Secondary therapy:
Hormone Therapy
DOI:
10.1200/JCO.22.00069